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diabetic PAI-1 +/+ mice, is weak when compared with
nondiabetic mice (×1.5), and is hardly distinguishable
from the induction observed in PAI-1 −/− mice, at least
for the eye (Fig. 3). Another striking result is that the
level of TGF-beta expression and production by the kid-
ney is higher in PAI-1 −/− mice than in PAI-1 +/+ mice,
in either basal or diabetic conditions. In the absence of
pathologic data, including measurements of the glomeru-
lar basement membrane thickness, it is therefore difficult
to conclude that PAI-1 knockout animals could be pro-
tected towards diabetic nephropathy and that this would
be related to a lower concentration of TGF-beta.
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Reply from the Authors
As we gain further insight into PAI-1–mediated mech-
anisms in disease, it is evident that PAI-1 may indeed
have several functions. Early studies showed that PAI-1
deficiency protects against fibrosis, as in the bleomycin-
induced pulmonary model [1], and this is supported by
our studies in the streptozotocin-induced diabetic mouse
model [2].
However, Hertig and Rondeau demonstrate that in in-
flammatory models of disease, PAI-1 deficiency may pro-
mote pathology. In fact, we have observed development
of cardiac fibrosis in PAI-1−/− mice (unpublished data),
as have Moriwaki et al [3], who also showed significant
macrophage involvement in this process. These observa-
tions strongly suggest that PAI-1 function may be deter-
mined by the inciting process, and modulated by uPA
expression, which may be tissue- or disease-specific.
The comment that induction of TGF-b synthesis is
weak (1.5 ×’s) reflects similar changes in total TGF-b
by Hertig et al (1.9 ×’s) [4]. Active TGF-b was not mea-
sured in our paper. As such, it is provocative to assume
that a seemingly “weak” stimulation of TGF-b protein
by PAI-1 may not have a significant clinical outcome (i.e.,
worsened albuminuria). Our data showed no significant
difference in basal kidney TGF-b expression, which was
significantly reduced in diabetic PAI-1−/− mice (Fig. 3).
Significant structural changes of diabetic nephropathy,
such as glomerular basement membrane thickness and
fractional mesangial volume, are not typically observed
after 4 weeks of diabetes in C57BL6 STZ-induced dia-
betic mice and, in fact, may not appear until ∼6 months
of diabetes. For this reason, these parameters were not
included in our study.
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Does fluvastatin really have an
antioxidant effect in humans?
To the Editor: In the recent issue of Kidney Interna-
tional, Pat et al demonstrated that renal fibrosis after
unilateral ureteral obstruction in rat was attenuated by
the antioxidative effect of fluvastatin [1], a HMG-CoA
reductase inhibitor notable for its additional antioxidant
effect [2]. We undertook this clinical experiment because
no in vivo human data are available addressing the antiox-
idant effect of fluvastatin. The patients studied consisted
of 3 males and 3 females, with an average age of 56.5
years. All had biopsy-proven chronic glomerulonephri-
tis with normal ranges of creatinine clearance and serum
total protein. The mean urinary protein excretion was
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Fig. 1. Serum total cholesterol (TC) and triglyceride (TG) decreased by the fluvastatin administration. Two markers of serum lipid peroxides,
thiobarbituric acid reactive substance (TBARS) and phosphatidylcholine hydroperoxide (PCOOH), did not decrease. Each bar represents the
mean ± SD.
0.35 g/day and serum total cholesterol (TC) was 262.3
mg/dL. After getting informed consent, serum was col-
lected once a month in the morning 2 to 3 hours after
breakfast. This was done 3 times prior to the administra-
tion of fluvastin and 3 times again after starting the drug.
Some patients were receiving antihypertensive drugs, the
dosages of which were unchanged throughout the exam-
ination period. No patients were administered steroids.
Thiobarbituric acid reactive substances (TBARS) and
phosphatidylcholine hydroperoxide (PCOOH) as indices
of lipid peroxidation [3, 4], and TC and triglyceride (TG)
as indices of lipid-lowering effect were measured (Fig. 1).
TC and TG levels were significantly decreased by the
administration of fluvastatin, while the levels of lipid per-
oxides did not decrease. In this study, we could not find
an in vivo antioxidant action of fluvastatin, although the
fall in TC and TG levels was clearly shown.
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C-reactive protein and
coronary heart disease in
hemodialyzed patients
To the Editor: A mounting tide of papers is showing a
close association between C-reactive protein (CRP) and
risk of acute coronary events in patients with coronary
heart disease [1, 2]. A recent Kidney International pa-
per [3] has also identified a relation between coronary
artery calcifications and CRP. In order to test a possible
association between CRP and acute episodes of coronary
ischemia, we have analyzed CRP levels in our hemodi-
alyzed patients with (CHD+) or without diagnosis of
coronary heart disease (Table 1). No differences were
observed between the 2 groups, although mean values
were above the normal range or 3 mg per L, a recently
suggested cut-off point for patients at risk of acute coro-
nary events [1]. Two patients of the CHD+ group showed
1 episode each of chest pain in the last 6 months, with
electrocardiographic changes and elevated levels of car-
diac enzymes. At the time of the myocardial infarct, CRP
